Catalyst Pharmaceuticals Competitors and Similar CompaniesClear all
Omeros's competitors and similar companies include Alnylam.
 Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 1994 | Founding Date 2002 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Seattle, US HQ | |
Employees | Employees 1968% decrease | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 248.6 m | Valuation ($) 36.5 b |
Financial | ||
Net income | Net income ($3.4m) (FY, 2025) | Net income $313.7m (FY, 2025) |
Funding | ||
Total funding raised | Total funding raised $ 354.8m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company